OKYO Pharma Limited Director/PDMR Shareholding (1394U)

TIDMOKYO

RNS Number : 1394U

OKYO Pharma Limited

24 March 2023

PDMR Dealing

London and New York, NY, 24 March, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ("DED") to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 of the Company's ADSs on NASDAQ at a price of US$1.40 per ADS (which would be equivalent to the purchase of 650,000 ordinary shares of no par value ("Ordinary Shares") at a price of GBP0.0175 each).

 
 1.    Details of PDMR / person closely associated 
 a)    Name                Gabriele Cerrone 
      ------------------  ----------------------------------------------------- 
 2.    Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position            Chairman 
        / status 
      ------------------  ----------------------------------------------------- 
 b)    Initial             Initial notification 
        notification 
        /amendment 
      ------------------  ----------------------------------------------------- 
 3.    Details of the issuer 
      ------------------------------------------------------------------------- 
 a)    Name                OKYO Pharma Limited 
      ------------------  ----------------------------------------------------- 
 b)    LEI                 213800VVN5CB56Y15A05 
      ------------------  ----------------------------------------------------- 
 4.    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      ------------------------------------------------------------------------- 
 a)    Description         ADSs representing 65 Ordinary Shares of no par value 
        of the 
        financial 
        instrument 
      ------------------  ----------------------------------------------------- 
 b)    Identification      ISIN for OKYO Pharma Limited GG00BD3FV870 
        code of 
        the Financial 
        Instrument 
      ------------------  ----------------------------------------------------- 
 c)    Nature              Market Purchase 
        of the 
        transaction 
      ------------------  ----------------------------------------------------- 
       Price(s) 
 d)     and volume(s)      $1.40 - 10,000 
      ------------------  ----------------------------------------------------- 
 f)    Date of             23 March 2023 
        the transaction 
      ------------------  ----------------------------------------------------- 
 g)    Place of            NASDAQ 
        the transaction 
      ------------------  ----------------------------------------------------- 
 

Enquiries:

 
 OKYO Pharma           Gary S. Jacob, Chief Executive 
  Limited               Officer                           [phone] 
 Investor Relations    Paul Spencer                       [phone] 
 
                       Robert Emmet, Optiva Securities 
 Broker                 Limited                           [phone] 
 

Notes for Editors:

About OKYO

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com .

About OK-101

OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHZZLBLXXLLBBV

(END) Dow Jones Newswires

March 24, 2023 03:00 ET (07:00 GMT)